Biochanin-A attenuates neuropathic pain in diabetic rats

被引:24
作者
Chundi, Venkateswarlu [1 ]
Challa, Siva Reddy [2 ]
Garikapati, Devala Rao [2 ]
Juvva, Giridhar [2 ]
Jampani, Anusha [2 ]
Pinnamaneni, Sree Harsha [2 ]
Venigalla, Sahithi [2 ]
机构
[1] PB Siddhartha Coll Arts & Sci, Dept Zool, Vijayawada 520010, Andhra Prades, India
[2] KVSR Siddhartha Coll Pharmaceut Sci, Dept Pharmacol, Vijayawada 520010, Andhra Prades, India
关键词
Allodynia; Diabetic neuropathy; Hyperalgesia; Isoflavone; Streptozotocin; Hyperglycemia; Paw withdrawal threshold; von Frey filaments;
D O I
10.1016/j.jaim.2016.08.001
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Background: Soya supplements are used in the treatment of neuropathic pain. Previous reports reveal that consumption of soy diet before nerve injury prevents the development of neuropathic pain in rats. Biochanin-A, a soy isoflavone, has a naturally occurring inhibitor of fatty acid amide hydrolase (FAAH) that metabolized endocannabinoids. Objective: The objective was to evaluate efficacy of biochanin-A in streptozotocin (STZ) induced neuropathic pain in rat model. Materials and methods: Diabetes mellitus was induced by an injection of STZ at a dose of 45 mg/kg, i.v. into tail vein of male albino Wistar rats. Biochanin-A was dosed at 0.1, 1 and 5 mg/kg by intraperitoneal (i.p.) administration in diabetic neuropathic rats. Mechanical hyperalgesia and allodynia was measured using Randall-Selitto analgesymeter and manual von Frey filaments of increasing weights respectively. Paw withdrawal threshold (PWT) and percent PWT was determined with respect to both hyperalgesia and allodynia. Results: Treatment of biochanin-A at three different levels of 0.1, 1 and 5 mg/kg had not significantly altered serum glucose levels throughout the treatment period. In hyperalgesia study, acute treatment with higher dose exhibited 51.1% reversal of paw withdrawal threshold (PWT) while with chronic treatment, efficacy declined to 22.5% reversal of PWT. In allodynia study, acute treatment reversed PWT by 79.4% while with chronic treatment, efficacy was raised to 88.2% reversal of PWT. Conclusion: Biochanin-A demonstrated better efficacy in reversing mechanical allodynia than mechanical hyperalgesia. Biochanin-A could be a good drug candidate for further studies to establish the mechanism of attenuation of neuropathic pain. (C) 2016 Transdisciplinary University, Bangalore and World Ayurveda Foundation. Publishing Services by Elsevier B.V.
引用
收藏
页码:231 / 237
页数:7
相关论文
共 28 条
[1]  
Annapurna A, 2009, J PHARM PHARMACOL, V61, P1365, DOI [10.1211/jpp/61.10.0014, 10.1211/jpp.61.10.0014]
[2]   Soya supplements in the treatment of neuropathic pain [J].
Bermejo, P. E. .
REVISTA DE NEUROLOGIA, 2007, 45 (08) :479-481
[3]   Spinal pharmacology of tactile allodynia in diabetic rats [J].
Calcutt, NA ;
Chaplan, SR .
BRITISH JOURNAL OF PHARMACOLOGY, 1997, 122 (07) :1478-1482
[4]   QUANTITATIVE ASSESSMENT OF TACTILE ALLODYNIA IN THE RAT PAW [J].
CHAPLAN, SR ;
BACH, FW ;
POGREL, JW ;
CHUNG, JM ;
YAKSH, TL .
JOURNAL OF NEUROSCIENCE METHODS, 1994, 53 (01) :55-63
[5]   Biochanin A protects dopaminergic neurons against lipopolysaccharide-induced damage through inhibition of microglia activation and proinflammatory factors generation [J].
Chen, Han-Qing ;
Jin, Zheng-Yu ;
Li, Guan-Hong .
NEUROSCIENCE LETTERS, 2007, 417 (02) :112-117
[6]   STREPTOZOCIN-INDUCED DIABETIC RATS - BEHAVIORAL EVIDENCE FOR A MODEL OF CHRONIC PAIN [J].
COURTEIX, C ;
ESCHALIER, A ;
LAVARENNE, J .
PAIN, 1993, 53 (01) :81-88
[7]   Thalamic neuron hyperexcitability and enlarged receptive fields in the STZ model of diabetic pain [J].
Fischer, Tanya Z. ;
Tan, Andrew M. ;
Waxman, Stephen G. .
BRAIN RESEARCH, 2009, 1268 :154-161
[8]   Antihyperglycemic effect of biochanin A, a soy isoflavone, on streptozotocin-diabetic rats [J].
Harini, Ranganathan ;
Ezhumalai, Muthukrishnan ;
Pugalendi, Kodukkur Viswanathan .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2012, 676 (1-3) :89-94
[9]  
Hounsom L, 1997, CLIN NEUROSCI, V4, P380
[10]   Role of vanilloid VR1 receptor in thermal allodynia and hyperalgesia in diabetic mice [J].
Kamei, J ;
Zushida, K ;
Morita, K ;
Sasaki, M ;
Tanaka, S .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 422 (1-3) :83-86